FBIOFortress Biotech, Inc.

Nasdaq fortressbiotech.com


$ 1.76 $ -0.05 (-2.78 %)    

Friday, 03-May-2024 15:59:51 EDT
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ 1.75
$ 1.83
$ 0.00 x 0
$ 0.00 x 0
$ 1.73 - $ 1.83
$ 1.24 - $ 11.50
177,764
na
14.19M
$ 1.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 08-14-2023 06-30-2023 10-Q
3 05-15-2023 03-31-2023 10-Q
4 03-31-2023 12-31-2022 10-K
5 11-14-2022 09-30-2022 10-Q
6 08-11-2022 06-30-2022 10-Q
7 05-12-2022 03-31-2022 10-Q
8 03-28-2022 12-31-2021 10-K
9 11-15-2021 09-30-2021 10-Q
10 08-16-2021 06-30-2021 10-Q
11 05-17-2021 03-31-2021 10-Q
12 03-31-2021 12-31-2020 10-K
13 11-09-2020 09-30-2020 10-Q
14 08-10-2020 06-30-2020 10-Q
15 05-11-2020 03-31-2020 10-Q
16 03-16-2020 12-31-2019 10-K
17 11-12-2019 09-30-2019 10-Q
18 08-09-2019 06-30-2019 10-Q
19 05-10-2019 03-31-2019 10-Q
20 03-18-2019 12-31-2018 10-K
21 11-09-2018 09-30-2018 10-Q
22 08-09-2018 06-30-2018 10-Q
23 05-10-2018 03-31-2018 10-Q
24 03-16-2018 12-31-2017 10-K
25 11-09-2017 09-30-2017 10-Q
26 08-09-2017 06-30-2017 10-Q
27 05-10-2017 03-31-2017 10-Q
28 03-16-2017 12-31-2016 10-K
29 11-09-2016 09-30-2016 10-Q
30 08-09-2016 06-30-2016 10-Q
31 05-10-2016 03-31-2016 10-Q
32 03-15-2016 12-31-2015 10-K
33 11-09-2015 09-30-2015 10-Q
34 08-10-2015 06-30-2015 10-Q
35 05-11-2015 03-31-2015 10-Q
36 03-16-2015 12-31-2014 10-K
37 11-06-2014 09-30-2014 10-Q
38 08-11-2014 06-30-2014 10-Q
39 05-12-2014 03-31-2014 10-Q
40 03-14-2014 12-31-2013 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fortress-biotech-q4-eps-053-beats-197-estimate-sales-1995m-beat-1489m-estimate

Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(1....

 alliance-global-partners-initiates-coverage-on-fortress-biotech-with-buy-rating-announces-price-target-of-5

Alliance Global Partners initiates coverage on Fortress Biotech (NASDAQ:FBIO) with a Buy rating and announces Price Target of...

 roth-mkm-reinstates-buy-on-fortress-biotech-announces-10-price-target

Roth MKM analyst Jason Wittes reinstates Fortress Biotech (NASDAQ:FBIO) with a Buy and announces $10 price target.

Core News & Articles

Half of the enrolled patients had stable disease for at least two months, two showed partial response and two experienced com...

 alzamend-neuro-and-3-other-stocks-under-3-insiders-are-buying

$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying

 fear--greed-index-remains-in-extreme-greed-zone-sp-500-surges-24-in-2023

The CNN Money Fear and Greed index showed some decline in overall market sentiment, but the index remained in the "Extreme ...

 gold-moves-lower-microbot-medical-shares-slide

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling more than 50 points on Friday. The Dow tr...

 why-fisker-shares-are-trading-higher-by-over-20-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Fisker Inc. (NYSE: FSR) rose sharply during Friday’s session after the company provided a December 2023 business upd...

 nasdaq-down-over-100-points-fortress-biotech-shares-plummet

U.S. stocks turned lower midway through trading, with the Nasdaq Composite falling more than 100 points on Friday. The Dow tra...

 why-fortress-biotech-shares-are-tumbling-today

Fortress Biotech Inc (NASDAQ: FBIO) shares are trading lower by over 18% after it announced the pricing of a 

 why-lantheus-holdings-shares-are-trading-lower-by-over-22-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma ann...

 cyprium-therapeutics-a-fortress-biotech-subsidiary-company-completes-asset-transfer-of-cutx-101-copper-histidinate-product-candidate-for-treatment-of-menkes-disease-to-sentynl-therapeutics-a-wholly-owned-subsidiary-of-zydus-lifesciences-ltd

Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregat...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION